Entheon Biomedical Corp. (OTC: ENTBF) a company dedicated to the application of the psychedelic DMT in the treatment of addiction, announced the launch of a psychedelics genetic test kit, through its wholly-owned subsidiary, HaluGen Life Sciences Inc.
The test will serve as a pre-screening platform for patients looking into psychedelics-assisted psychotherapy, giving out “genetic, personal and familial insights” to improve patient care and reduce possible risks associated with the therapy.
"For Entheon, the launch of this product also represents our first revenue stream as we work to develop commercial partnerships for the mass sale of the test,” said CEO Timothy Ko.
The company said the test is now available for sale in Canada, and expects to offer availability in the U.S. in coming months.
How Does It Work?
The technology, which has existed in similar variants in the cannabis industry for a few years, is a psychedelics first, according to the company.
Clients receive a simple test kit in their home, do a cheek swab and return the kit to the company, which conducts a PCR genetic analysis at its Toronto testing facility.
“A personalized genetic profile with five individualized sensitivity and risk reports is sent directly to the customer and they are also given access to pre-screening mental health surveys and relevant peer-reviewed scientific studies,” said a release from the company.
Photo by Mufid Majnun on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Top Cannabis Event In New Jersey
Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!